Evaluation of a Real-World In-Hospital Antiplatelet-Switching Strategy Following Coronary Interventions: The SWITCH Study
CONCLUSIONS: A strategy of using newer, fast-acting, and reliable antiplatelet agents prior to PCI and acutely switching to long-term clopidogrel therapy appears safe and efficacious. Although the superiority of the newer antiplatelet agents for long-term post-PCI dual-antiplatelet therapy in a trial setting is well established, the impact of increased adherence to lower-cost clopidogrel therapy in the real-world setting merits further consideration.PMID:33794478
Source: The Journal of Invasive Cardiology - Category: Cardiology Authors: Antoine E Soueid Ibrahim Kassas Jeffrey Rade Nikolaos Kakouros Source Type: research
More News: Angioplasty | Bleeding | Cardiology | Clopidogrel | Coronary Angioplasty | Heart | Percutaneous Coronary Intervention | Plavix | Study | Thrombosis